British pharma giant AstraZeneca PLC said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown "encouraging" responses among elderly, as well as younger participants.
The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed "strong immune responses" in all adult groups during the previous stage, according to an update from Oxford.
An AstraZeneca spokesman said the initial results "further build the body of evidence for the safety and immunogenicity" of its experimental vaccine.
"It is encouraging to see immunogenicity responses were similar between older and younger adults, the spokesman added.